Directors who control the board of Cerebral Inc. agreed on a plan to replace Chief Executive Kyle Robertson, sparking leadership tumult at the mental-health startup as it contends with scrutiny over its prescription practices for controlled substances, people familiar with the situation said Tuesday.
Investors and an independent director who together control four of the board’s seven seats agreed that Mr. Robertson should be replaced by the firm’s president and chief medical officer, David Mou, some of the people said. Mr. Robertson, who is also Cerebral’s co-founder and controls the other three seats, didn’t participate in the meeting, but afterward he lost access to the company’s Slack messaging system without advance notice, another person said. Mr. Robertson hadn’t agreed to depart his CEO role as of late Tuesday, the people said.
